Quantcast

Latest Fentanyl Stories

2014-05-07 08:33:35

CUPERTINO, Calif., May 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at the Bay Area Prescription Drug Abuse Summit on May 7, 2014 in San Francisco. The summit is an effort to bring together senior policymakers, medical professionals, educators, local, state and federal law enforcement and the community to seek solutions to this problem and to raise awareness of the...

2014-05-04 23:00:50

ReportsnReports.com adds “Transdermal Drug Delivery Market & Clinical Pipeline Insight” report to its research database. Dallas, Texas (PRWEB) May 04, 2014 Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is...

2014-05-01 16:32:50

CUPERTINO, Calif., May 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014. Total revenues were $6.3 million and net loss was $3.6 million for the three months ended March 31, 2014 as compared to total revenues of $4.2 million and net loss of $5.2 million for the three months ended March 31, 2013. At March 31, 2014, we had cash and investments of $21.8 million, compared to cash and investments of $24.4 million at December...

2014-05-01 08:35:48

REDWOOD CITY, Calif., May 1, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and ARX-04 data presentations will be made at the American Pain Society's (APS) 33(rd) Annual Scientific Meeting held on April 30 to May 3 in Tampa, Florida. The APS Annual Scientific Meeting is the...

2014-04-30 16:30:40

NEWARK, Calif., April 30, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2014 financial results after the market closes on Thursday, May 8, 2014. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2014-04-23 20:23:13

CUPERTINO, Calif., April 23, 2014 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 1, 2014 at 4:30 pm Eastern Time (1:30 pm Pacific Time). http://photos.prnewswire.com/prnvar/20020717/DRRXLOGO A live audio webcast of the presentation will be available by accessing DURECT's homepage at...

2014-04-14 12:33:34

NEWARK, Calif., April 14, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise(®) (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on...

2014-04-07 12:32:56

First presentation of detailed BUNAVAIL clinical data scheduled for April 11 and 13, 2014 RALEIGH, N.C., April 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45(th) Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida. Four abstracts will be presented highlighting data from the clinical development...

2014-04-01 16:25:48

CUPERTINO, Calif., April 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39(th) Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago....

2014-03-14 08:26:42

BUNAVAIL PDUFA date June 7, 2014; Plans underway for potential Q3 2014 launch RALEIGH, N.C., March 14, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related